Carcinoma in situ of the bladder: why is it underdetected?
Authors:
- 23 March 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 30 (3) , 392-399
Abstract
Purpose of review The standard diagnosis of carcinoma in situ (CIS) of the bladder, based on white light cystoscopy and urine cytology, is limited because CIS can vary from normal-appearing mucosa to a lesion indistinguishable from an inflammatory process. Intravesical instillation of Bacillus Calmette–Guerin (BCG) remains first-line therapy; however, a significant proportion of cases persist or recur after BCG treatment. This review summarizes recent improvements in the detection and treatment of CIS. Recent findings The new optical technologies improve CIS detection, with a potential positive impact on oncological outcomes. The usefulness of MRI-photodynamic diagnosis fusion transurethral resection in CIS detection is unclear and further studies are needed. BCG instillation remains the first-line therapy in CIS patients and seems to improve recurrence and progression rates, especially with the use of maintenance. Intravesical device-assisted therapies could be effective in both BCG-naïve and BCG-unresponsive CIS patients, but further studies are ongoing to clarify their clinical benefit. A phase II clinical trial with pembrolizumab has shown the potential effectiveness of immune checkpoint inhibitors in BCG-unresponsive CIS patients and further trials are ongoing. Summary New optical techniques increase the CIS detection rate. BCG instillation remains the first-line treatment. Immune checkpoint inhibitors could be a future alternative in BCG-naïve and BCG-unresponsive CIS patients.Keywords
This publication has 48 references indexed in Scilit:
- Diagnosis of narrow‐band imaging in non‐muscle‐invasive bladder cancer: A systematic review and meta‐analysisInternational Journal of Urology, 2012
- Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladderUrologic Oncology: Seminars and Original Investigations, 2012
- Maintenance intravesical bacillus Calmette‐Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study GroupInternational Journal of Urology, 2010
- Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progressionUrologic Oncology: Seminars and Original Investigations, 2010
- Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette‐Guérin immunotherapy?BJU International, 2009
- Clinical outcomes of bacillus Calmette‐Guérin instillation therapy for carcinoma in situ of urinary bladderInternational Journal of Urology, 2008
- Long-term Outcome of a Low-dose Intravesical Bacillus Calmette–Guerin Therapy for Carcinoma In Situ of the Bladder: Results After Six Successive Instillations of 40 mg BCGJapanese Journal of Clinical Oncology, 2005
- Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancerBJU International, 2002
- EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDERJournal of Urology, 2000
- Significance of Bladder Biopsies in Ta,T1 Bladder Tumors: A Report from the EORTC Genito-Urinary Tract Cancer Cooperative GroupEuropean Urology, 1999